Sangui Bio Tech International Inc.
EANS-News: Sangui Bio Tech International Inc.
Granulox has positive influence
on healing of leg ulcers
-------------------------------------------------------------------------------- Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Research & Development/Clinical study Witten, German, December 12, 2012 (euro adhoc) - Most extensive clinical study so far at Karls University in Prague shows Granulox has positive influence on healing of leg ulcers Results to be published in issue 3/2013 of renowned medical journal Witten, Germany, December 12, 2012 A report on the course and results of a comparative clinical study carried out under the direction of professor Petr Arenberger, MD, at the clinic of dermatology at the Karls University in Prague was now accepted for publication. The study aimed to investigate into the influence of a hemoglobin based spray on the healing progress of leg ulcer. Leg ulcer is one the most prolific origins of chronic wounds with a prevalence of about 1.5 million cases p. a. in Germany alone. This was the most extensive clinical study regarding this technology to support wound healing as developed by Sangui. The prospective, randomized and placebo controlled study gave highly significant evidence that there is a clearly positive influence of the hemoglobin spray on wound healing. The eminent efficacy of Granulox (e. g. in patients suffering from leg ulcer) is now documented one more time on the highest scientific level. The entire study including all findings, in particular regarding the improvement of healing times and the reduction of pain experienced by the patients will be published in the 3/2013 issue of "Der Hautarzt" (Springer Verlag (Heidelberg)). "Der Hautarzt" enjoys international acceptance and is amply quoted. The journal informs clinical and practising dermatologists on a regular basis of all important developments in all areas of dermatology. Articles are not published unless they have passed a peer review. Further inquiry note: Dr. Joachim Fleing Fon: +49 (179) 7963472 Fax: +49 (2302) 915191 e-mail: fleing@sangui.de end of announcement euro adhoc -------------------------------------------------------------------------------- company: Sangui Bio Tech International Inc. Alfred-Herrhausen-Strasse 44 D-58455 Witten phone: +49(0)2302 915-200 FAX: +49(0)2302 915-191 mail: info@sangui.de WWW: http://www.sanguibiotech.com sector: Biotechnology ISIN: DE0000906757 indexes: stockmarkets: free trade: Hamburg, New York language: English